SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Genmab Reports Phase 2 Data Showing Over Two-Year Median Survival

The company reported median overall survival outcomes with petosemtamab plus pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma.

GMAB

Related stories